A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
Sponsor: Novartis Pharmaceuticals
This PHASE2 trial investigates Recurrent Glioblastoma or Other Glioma Subtypes and is currently completed. Novartis Pharmaceuticals leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2019 — Jan 2020 [monthly]
Completed PHASE2
-
Apr 2019 — May 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .